Pediatric rheumatology

Uveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

Younger age at onset, uveitis, duration of tapering, and non-persistent oligoarticular JIA seem to be independent risk factors for earlier relapse after the first TNFi withdrawal.

Study context

Population
Patients with oligoarticular and polyarticular juvenile idiopathic arthritis (JIA) who stopped the first TNF inhibitors (TNFi) (adalimumab or etanercept) for persistent inactivity, Italy102 female
Participants
136 patients
Exposure
Adalimumab vs Etanercept
Outcome
Disease relapse after first TNFi withdrawal and associated factors
Methodological detailsmulticentre
  • Multicentre

Main finding

As reported in the abstract

Relapse after TNFi withdrawal
Patients relapsed
79.4%
Median time to relapse, months (range 0.5-66)
5
Uveitis, predictor of relapse
2.11 (HR, CI 1.34-3.31)
Age at onset, predictor of relapse
0.909 (HR, CI 0.836-0.987)
Duration of tapering, predictor of relapse
0.938 (HR, CI 0.893-0.985)
Persistent oligoarticular JIA, predictor of relapse
0.597 (HR, CI 0.368-0.968)
Overall model (Mantel-Cox χ² 34.23)
p<0.001

Observational data: associations, not effects.

Further findings

Time to relapse by uveitis

Patients with uveitis relapsed earlier (log rank χ² 16.4)
P < 0.0001

Time to relapse by tapering by lengthening interval

Patients who lengthened the interval showed a later relapse (log rank χ² 6.95)
P = 0.008

Original publication

Uveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience. Clin Exp Rheumatol. Published 20 August 2023. doi:10.55563/clinexprheumatol/3mxsll

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.